Sorrento Therapeutics Company Profile (NASDAQ:SRNE)

About Sorrento Therapeutics (NASDAQ:SRNE)

Sorrento Therapeutics logoSorrento Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, acquisition, development and commercialization of drug therapeutics. Its primary therapeutic focus is oncology, including the treatment of chronic cancer pain. It is also developing therapeutic products for other indications, including immunology and infectious diseases. Its products in the pipeline include Chimeric Antigen Receptor-T Cell (CAR-T) programs, resiniferatoxin (RTX), and biosimilar/biobetter antibodies clinical development programs. Its pipeline also includes preclinical fully human therapeutic monoclonal antibodies (mAbs), including biosimilars/biobetters, fully human anti-PD-L1 and anti-PD-1 checkpoint inhibitors derived from its G-MAB library platform, antibody drug conjugates (ADCs), bispecific antibodies (BsAbs), as well as CAR-T and Chimeric Antigen Receptor Natural Killer (NK) cells (CAR. NK) for adoptive cellular immunotherapy.

Industry, Sector and Symbol: Capitalization:
  • Market Cap: $196.3 million
  • Outstanding Shares: 68,971,000
Average Prices:
  • 50 Day Moving Avg: $2.06
  • 200 Day Moving Avg: $1.95
  • 52 Week Range: $1.50 - $7.08
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.31
  • P/E Growth: -0.07
Sales & Book Value:
  • Annual Revenue: $15.8 million
  • Price / Sales: 12.22
  • Book Value: $1.34 per share
  • Price / Book: 2.09
  • EBITDA: ($69,490,000.00)
  • Net Margins: -257.85%
  • Return on Equity: -96.66%
  • Return on Assets: -21.74%
  • Debt-to-Equity Ratio: 0.28%
  • Current Ratio: 0.76%
  • Quick Ratio: 0.76%
  • Average Volume: 1.04 million shs.
  • Beta: 1.53
  • Short Ratio: 4.99

Frequently Asked Questions for Sorrento Therapeutics (NASDAQ:SRNE)

What is Sorrento Therapeutics' stock symbol?

Sorrento Therapeutics trades on the NASDAQ under the ticker symbol "SRNE."

How were Sorrento Therapeutics' earnings last quarter?

Sorrento Therapeutics, Inc. (NASDAQ:SRNE) issued its earnings results on Monday, November, 16th. The company reported ($0.03) EPS for the quarter. The firm earned $1.10 million during the quarter, compared to analyst estimates of $1.28 million. Sorrento Therapeutics had a negative net margin of 257.85% and a negative return on equity of 96.66%. View Sorrento Therapeutics' Earnings History.

Where is Sorrento Therapeutics' stock going? Where will Sorrento Therapeutics' stock price be in 2017?

5 equities research analysts have issued 1-year price targets for Sorrento Therapeutics' stock. Their predictions range from $7.00 to $20.00. On average, they anticipate Sorrento Therapeutics' stock price to reach $12.60 in the next twelve months. View Analyst Ratings for Sorrento Therapeutics.

Are investors shorting Sorrento Therapeutics?

Sorrento Therapeutics saw a decrease in short interest during the month of September. As of September 29th, there was short interest totalling 1,723,482 shares, a decrease of 33.8% from the September 15th total of 2,605,018 shares. Based on an average daily trading volume, of 415,992 shares, the days-to-cover ratio is presently 4.1 days. Currently, 4.2% of the shares of the company are sold short.

Who are some of Sorrento Therapeutics' key competitors?

Who are Sorrento Therapeutics' key executives?

Sorrento Therapeutics' management team includes the folowing people:

  • William S. Marth, Independent Chairman of the Board
  • Henry H. Ji Ph.D., President, Chief Executive Officer, Director
  • Kevin Herde, Chief Financial Officer, Executive Vice President
  • Mike Royal M.D., Executive Vice President - Clinical and Regulatory Affairs
  • Miranda Jayne Toledano, Executive Vice President - Corporate Development
  • George Uy, Executive Vice President, Chief Commercial Officer
  • David Miao, Chief Technology Officer
  • Jaisim Shah, Director
  • Yue Wu Ph.D., Director
  • David H. Deming, Independent Director

How do I buy Sorrento Therapeutics stock?

Shares of Sorrento Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sorrento Therapeutics' stock price today?

One share of Sorrento Therapeutics stock can currently be purchased for approximately $2.80.

MarketBeat Community Rating for Sorrento Therapeutics (NASDAQ SRNE)
Community Ranking:  4.2 out of 5 (star star star star)
Outperform Votes:  208 (Vote Outperform)
Underperform Votes:  39 (Vote Underperform)
Total Votes:  247
MarketBeat's community ratings are surveys of what our community members think about Sorrento Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Sorrento Therapeutics (NASDAQ:SRNE) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $12.60 (350.00% upside)
Consensus Price Target History for Sorrento Therapeutics (NASDAQ:SRNE)
Price Target History for Sorrento Therapeutics (NASDAQ:SRNE)
Analysts' Ratings History for Sorrento Therapeutics (NASDAQ:SRNE)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/5/2017HC WainwrightReiterated RatingBuy$20.00N/AView Rating Details
8/29/2017Oppenheimer Holdings, Inc.Set Price TargetBuy$7.00HighView Rating Details
8/3/2017Roth CapitalInitiated CoverageBuy$7.00HighView Rating Details
6/17/2017FBR & CoReiterated RatingBuyLowView Rating Details
5/22/2017Rodman & RenshawLower Price TargetBuy -> Buy$30.00 -> $20.00HighView Rating Details
8/12/2016Brean CapitalReiterated RatingBuyN/AView Rating Details
(Data available from 10/21/2015 forward)


Earnings History for Sorrento Therapeutics (NASDAQ:SRNE)
Earnings by Quarter for Sorrento Therapeutics (NASDAQ:SRNE)
Earnings History by Quarter for Sorrento Therapeutics (NASDAQ SRNE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/16/2015Q315($0.03)$1.28 million$1.10 millionViewN/AView Earnings Details
11/4/2014Q314($0.32)($0.27)$0.08 million$1.28 millionViewN/AView Earnings Details
8/6/2014($0.34)($0.33)$0.08 million$0.78 millionViewN/AView Earnings Details
5/14/2014($0.29)($0.44)$0.12 million$0.98 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Sorrento Therapeutics (NASDAQ:SRNE)
2017 EPS Consensus Estimate: ($1.25)
2018 EPS Consensus Estimate: ($0.54)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.33)($0.33)($0.33)
Q2 20171($0.34)($0.34)($0.34)
Q3 20172($0.35)($0.21)($0.28)
Q4 20172($0.38)($0.21)($0.30)
Q1 20181$0.02$0.02$0.02
Q2 20181($0.19)($0.19)($0.19)
Q3 20181($0.19)($0.19)($0.19)
Q4 20181($0.18)($0.18)($0.18)
Q1 20191($0.16)($0.16)($0.16)
Q2 20191$0.24$0.24$0.24
(Data provided by Zacks Investment Research)


Dividend History for Sorrento Therapeutics (NASDAQ:SRNE)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Sorrento Therapeutics (NASDAQ:SRNE)
Insider Ownership Percentage: 5.00%
Institutional Ownership Percentage: 15.83%
Insider Trades by Quarter for Sorrento Therapeutics (NASDAQ:SRNE)
Institutional Ownership by Quarter for Sorrento Therapeutics (NASDAQ:SRNE)
Insider Trades by Quarter for Sorrento Therapeutics (NASDAQ:SRNE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/15/2017Henry JiInsiderBuy29,001$1.81$52,491.81View SEC Filing  
6/15/2017Jaisim ShahDirectorBuy10,002$1.79$17,903.58View SEC Filing  
4/19/2017Abg Management LtdMajor ShareholderBuy550,000$2.00$1,100,000.00View SEC Filing  
4/19/2017Henry JiCEOBuy100,000$2.00$200,000.00View SEC Filing  
4/13/2017Abg Management LtdMajor ShareholderBuy2,500,000$2.00$5,000,000.00View SEC Filing  
2/22/2017Henry JiInsiderBuy2,000$5.60$11,200.00View SEC Filing  
2/10/2017Henry JiInsiderBuy20,000$5.15$103,000.00View SEC Filing  
2/3/2017Jerome B ZeldisInsiderBuy10,000$5.15$51,500.00View SEC Filing  
2/3/2017Kevin HerdeVPBuy3,000$5.15$15,450.00View SEC Filing  
2/3/2017Yue Alexander WuDirectorBuy5,000$5.15$25,750.00View SEC Filing  
6/29/2016Patrick Soon-ShiongMajor ShareholderSell3,400$5.82$19,788.00View SEC Filing  
6/23/2016Patrick Soon-ShiongMajor ShareholderSell6,901$5.85$40,370.85View SEC Filing  
6/15/2016Patrick Soon-ShiongMajor ShareholderSell19,836$5.87$116,437.32View SEC Filing  
6/14/2016Patrick Soon-ShiongMajor ShareholderSell53,764$6.14$330,110.96View SEC Filing  
6/13/2016Patrick Soon-ShiongMajor ShareholderSell37,792$6.15$232,420.80View SEC Filing  
3/7/2016Patrick Soon-ShiongMajor ShareholderSell100,000$6.19$619,000.00View SEC Filing  
8/26/2015Henry JiCEOBuy500$0.95$475.00View SEC Filing  
8/24/2015Henry JiCEOBuy8,888$12.84$114,121.92View SEC Filing  
8/21/2015Henry JiCEOBuy8,888$13.08$116,255.04View SEC Filing  
11/10/2014Henry JiCEOBuy5,999$4.83$28,975.17View SEC Filing  
11/7/2014Henry JiCEOBuy4,000$4.56$18,240.00View SEC Filing  
11/6/2014Henry JiCEOBuy3,000$4.53$13,590.00View SEC Filing  
12/5/2013Henry JiCEOBuy1,000$8.92$8,920.00View SEC Filing  
12/4/2013Henry JiCEOBuy1,000$8.54$8,540.00View SEC Filing  
11/25/2013Jaisim ShahDirectorBuy1,000$8.65$8,650.00View SEC Filing  
11/22/2013Henry JiCEOBuy1,000$8.47$8,470.00View SEC Filing  
11/22/2013Opko Health, Inc.Major ShareholderSell8,471$8.50$72,003.50View SEC Filing  
11/21/2013George UyInsiderBuy3,000$8.36$25,080.00View SEC Filing  
11/21/2013Opko Health, Inc.Major ShareholderSell4,269$8.53$36,414.57View SEC Filing  
11/20/2013Opko Health, Inc.Major ShareholderSell17,062$8.75$149,292.50View SEC Filing  
11/19/2013George UyInsiderBuy2,031$8.61$17,486.91View SEC Filing  
11/19/2013Henry JiCEOBuy2,000$8.59$17,180.00View SEC Filing  
11/19/2013Jaisim ShahDirectorBuy1,000$9.00$9,000.00View SEC Filing  
11/15/2013Opko Health, Inc.Major ShareholderSell2,710$8.75$23,712.50View SEC Filing  
11/14/2013Opko Health, Inc.Major ShareholderSell1,900$8.75$16,625.00View SEC Filing  
11/13/2013Opko Health, Inc.Major ShareholderSell13,457$8.75$117,748.75View SEC Filing  
11/8/2013Opko Health, Inc.Major ShareholderSell2,000$8.75$17,500.00View SEC Filing  
11/7/2013Opko Health, Inc.Major ShareholderSell120,380$9.03$1,087,031.40View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Sorrento Therapeutics (NASDAQ:SRNE)
Latest Headlines for Sorrento Therapeutics (NASDAQ:SRNE)
DateHeadline logoSorrento Therapeutics, Inc. (SRNE) Given Average Rating of "Buy" by Brokerages - October 17 at 2:52 AM logoSorrento Therapeutics, Inc. (SRNE) Sees Significant Decrease in Short Interest - October 15 at 2:20 AM logoETFs with exposure to Sorrento Therapeutics, Inc. : October 10, 2017 - October 11 at 8:04 AM logoHead-To-Head Survey: Sorrento Therapeutics (SRNE) and Epizyme (EPZM) - October 11 at 6:28 AM logoH.C. Wainwright Sees Over 1000% Upside for Sorrento Therapeutics (SRNE) - October 6 at 12:46 PM logoSorrento Therapeutics, Inc. (SRNE) Stock Rating Reaffirmed by HC Wainwright - October 5 at 4:56 PM logoTechnical Insights on Biotech Stocks -- Cymabay Therapeutics, Cytori Therapeutics, CytRx, and Sorrento Therapeutics - October 3 at 12:52 PM logoSorrento Therapeutics Appoints Mr. Dorman Followwill And Mr. Dave Lemus To The Board Of Directors - October 2 at 9:16 AM logoSorrento Therapeutics, Inc. (SRNE) Given Consensus Rating of "Buy" by Brokerages - September 22 at 2:34 AM logoSorrento Therapeutics, Inc. To Present At Cantor Global Healthcare Conference (09/25/17 - 2:25 PM ET) - September 20 at 9:26 AM logoSorrento Therapeutics, Inc. (SRNE) Given Buy Rating at HC Wainwright - September 18 at 10:16 PM logoFDA Acknowledges Receipt Of Sorrento Therapeutics Inc, NDA For ZTlido™; PDUFA Date Set For February 28, 2018 - September 12 at 10:14 AM logoSorrento Therapeutics, Inc. To Present At 19th Rodman And Renshaw Global Investment Conference (09/11/17 - 17:30 ET) - September 9 at 8:52 AM logoETFs with exposure to Sorrento Therapeutics, Inc. : September 1, 2017 - September 4 at 6:52 AM logoETFs with exposure to Sorrento Therapeutics, Inc. : September 1, 2017 - September 1 at 9:07 AM logoSorrento Therapeutics (SRNE) Submits ZTlido NDA - August 31 at 10:24 AM logoFY2017 Earnings Forecast for Sorrento Therapeutics, Inc. (SRNE) Issued By Oppenheimer Holdings - August 31 at 9:06 AM logoSorrento Therapeutics, Inc. to Post Q1 2019 Earnings of ($0.16) Per Share, Oppenheimer Holdings Forecasts (SRNE) - August 30 at 1:28 PM logoHC Wainwright Analysts Give Sorrento Therapeutics, Inc. (SRNE) a $20.00 Price Target - August 30 at 11:16 AM logoSorrento Therapeutics (SRNE) Submits ZTlido NDA - - August 30 at 9:35 AM logoOppenheimer Holdings, Inc. Analysts Give Sorrento Therapeutics, Inc. (SRNE) a $7.00 Price Target - August 29 at 4:46 PM logoSorrento Therapeutics, Inc. Submits NDA For ZTlido™ Next-Generation Lidocaine Patch - August 29 at 8:11 AM logoSorrento Therapeutics, Inc. (SRNE) Given Consensus Rating of "Buy" by Analysts - August 28 at 2:36 AM logoSorrento Therapeutics, Inc. :SRNE-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017 - August 25 at 4:30 PM logoSorrento Therapeutics (SRNE): Celularity Deal Could Generate Allogeneic Products - Oppenheimer - - August 23 at 11:57 AM logoSorrento Contributes To The Formation Of Celularity, Inc. For Breakthrough Placental Therapeutic Platform In Consortium With Leading Pharmaceutical Companies - August 23 at 11:57 AM logoQ3 2017 EPS Estimates for Sorrento Therapeutics, Inc. (NASDAQ:SRNE) Increased by Analyst - August 14 at 2:06 AM logo-$0.34 EPS Expected for Sorrento Therapeutics, Inc. (NASDAQ:SRNE) This Quarter - August 13 at 10:30 AM logoSorrento Therapeutics, Inc. Expected to Post FY2021 Earnings of $0.44 Per Share (NASDAQ:SRNE) - August 11 at 5:22 PM logoSorrento Therapeutics, Inc. (NASDAQ:SRNE) Receives New Coverage from Analysts at Oppenheimer Holdings, Inc. - August 6 at 8:28 PM logoSorrento Therapeutics, Inc. (SRNE) Now Covered by Analysts at Roth Capital - August 3 at 6:38 PM logoSorrento Therapeutics, Inc. (NASDAQ:SRNE) Given Consensus Recommendation of "Buy" by Analysts - August 3 at 6:34 PM logoSorrento Therapeutics, Inc. (NASDAQ:SRNE) Now Covered by UBS AG - August 3 at 5:24 PM logo Analysts Anticipate Sorrento Therapeutics, Inc. (NASDAQ:SRNE) Will Post Quarterly Sales of $4.40 Million - July 28 at 7:52 PM logo$4.40 Million in Sales Expected for Sorrento Therapeutics, Inc. (NASDAQ:SRNE) This Quarter - July 2 at 11:02 AM logoSorrento Therapeutics (SRNE) Reports FDA Authorization of IND to Commence Clinical Trial of RTX in Intractable Cancer Pain - July 1 at 7:48 AM logoETFs with exposure to Sorrento Therapeutics, Inc. : June 30, 2017 - July 1 at 7:48 AM logoHealth Care Sector Update for 06/29/2017: SRNE,OBSV,BLCM - Nasdaq - June 30 at 6:56 AM logoSorrento Therapeutics Announced FDA Authorization of IND to ... - PR Newswire (press release) - June 30 at 6:56 AM logoSorrento Therapeutics (SRNE) Subsidiary Announces Positive Data from Head to Head Adhesion Study with ZTlido - June 15 at 9:23 PM logoSorrento Therapeutics Contributes to the Formation of Celularity, Inc. - PR Newswire (press release) - June 15 at 1:13 AM logoTechnical Insights on Biotech Stocks -- Soligenix, Sorrento Therapeutics, Alcobra, and Akebia Therapeutics - PR Newswire (press release) - June 9 at 8:49 AM logoSorrento Therapeutics (SRNE) Announces Completion of GMP Manufacturing Plant in Suzhou, China - - May 4 at 8:41 PM logoOpioid-fighting startup lands CEO, COO with deep pharmaceutical expertise - May 3 at 6:10 PM logoSorrento Therapeutics Announces Closing of its Acquisition of Virttu Biologics - PR Newswire (press release) - April 30 at 3:32 PM logoSorrento Therapeutics Announces Closing of its Acquisition of Virttu Biologics - PR Newswire (press release) - April 30 at 3:32 PM logoSorrento Therapeutics up 9% as CEO adds to stake - April 19 at 7:58 PM logoSorrento Therapeutics (SRNE) Prices 23.63M Common Stock Offering at $2/Share - - April 15 at 6:35 PM logoSorrento Therapeutics (SRNE) Plans Offering of Common Stock - - April 14 at 3:43 PM logoSorrento Therapeutics (SRNE) Phase Ib Study of anti-CEA CAR-T Shows Promising Clinical Activity and Safety - - April 4 at 8:27 AM



Sorrento Therapeutics (SRNE) Chart for Saturday, October, 21, 2017

This page was last updated on 10/21/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.